-
Product Insights
Net Present Value Model: CpG 1018
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CpG 1018 Drug Details Vaccine candidate...
-
Product Insights
Net Present Value Model: Heplisav-B
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Heplisav-B Drug Details Hepatitis B vaccine...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Gene therapy for cancers
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Gene therapy for cancers segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Z-1018
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Z-1018 Drug Details Z-1018 is under development for the prevention of herpes zoster (shingles)...
-
Product Insights
Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Shingles (herpes zoster) is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain, and swollen glands. The predisposing factors include age and a weakened immune system. The Herpes Zoster (Shingles) pipeline drugs market research report provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Rheumatoid Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to the destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue and fever, and weight loss. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications, and immunosuppressants. The Rheumatoid Arthritis Drugs in Development market research report provides an overview of the Rheumatoid Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage...
-
Product Insights
Anthrax Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Anthrax pipeline market research report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.
-
Product Insights
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll-like receptor 8 is a protein encoded by the TLR8 gene. It acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The Toll Like Receptor 8 (CD288 or TLR8) Development market research report provides an in-depth analysis of Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast – Q3, 2020
This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 23 drugs indicated for COVID-19 which have analyst consensus forecasts available.